header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

O3098 BOTULINUM TOXIN TYPE A IN THE TREATMENT OF CEREBRAL PALSY



Abstract

Aims: The aim of this study is to evaluate the effectiveness of a treatment with botulinum toxin type A (BTX-A) in children affected by CP. Methods: Between May 2001 and July 2002, we treated 12 children affected by CP: 11 males, 1 female, mean age 6,42 years; 1 child suffered from tetraplegia, 5 from diplegia and 6 from emiplegia. The injection was carried out in gastrocne-mius muscle (medial and lateral) in 11 patients, in hamstrings in 1 patients in a dose of 6 Units per kg of body weight per muscle. Post-injective treatment included intense physical therapy and orthoses. A clinical and video-recording evaluation, Gross scale and gait-EMG were carried out before injection and 1,3,6 months after. Results: BTX-A treatment has a good functional result: at the þrst control after injection all patients had a complete foot-ground contact instead of toe contact during stance and gait. Conclusion: The results of BTX-A treatment are positive, accordingly to literature: in all patients there was a reduction of spasticity and a complete foot-ground contact, with functional improvement in stance and gait. Good results can be achieved only if the indication is correct: spasticity of the muscle without muscle-tendinous retraction. BTX-A treatment has an effective role in the management of children suffering from CP, where there is no indication for surgical treatment.

Theses abstracts were prepared by Professor Dr. Frantz Langlais. Correspondence should be addressed to him at EFORT Central Office, Freihofstrasse 22, CH-8700 Küsnacht, Switzerland.